HIV Infections Clinical Trial
— ASPIRESOfficial title:
A Randomized Study Evaluating an Intervention Integrating Economic Strengthening and HIV Prevention Programs for Vulnerable Youth in South Africa
| NCT number | NCT02888678 |
| Other study ID # | 741818 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | February 2016 |
| Est. completion date | May 31, 2018 |
| Verified date | June 2018 |
| Source | FHI 360 |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study evaluates whether the integration of an Economic Strengthening program with an HIV-prevention education program produce synergistic effects on economic and health outcomes for South African youth ages 14-17 years old.
| Status | Completed |
| Enrollment | 1773 |
| Est. completion date | May 31, 2018 |
| Est. primary completion date | May 31, 2018 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 14 Years to 17 Years |
| Eligibility |
Inclusion Criteria: - Beneficiary of Future Families in a study community - Parent or guardian consent allowing adolescent to participate in the study - Willing to sign or make their mark on an assent form - Willing to provide contact information - Only one adolescent is eligible per household |
| Country | Name | City | State |
|---|---|---|---|
| South Africa | community Based Recruitment | Pretoria | Gauteng |
| Lead Sponsor | Collaborator |
|---|---|
| FHI 360 | Foundation for Professional Development, Future Families |
South Africa,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | STI prevalence Endline 1 | Prevalence of gonorrhea, trichomoniasis or chlamydia infection (lab report) | Nine months after baseline interview | |
| Primary | STI prevalence Endline 2 | Prevalence of gonorrhea, trichomoniasis or chlamydia infection (lab report) | eighteen months after baseline interview | |
| Secondary | Prevalence of pregnancy Endline 1 | Prevalence of pregnancy among female participants (lab report) | Nine months after baseline interview | |
| Secondary | Prevalence of pregnancy Endline 2 | Prevalence of pregnancy among female participants (lab report) | eighteen months after baseline interview | |
| Secondary | Percent of adolescents engaging in protective sexual behavior Endline 1 | Percent of adolescents engaging in protective sexual behavior, defined as self-reported abstinence or consistent condom use (a condom used every time) over the past 6 months | In the 6 month time period prior to the date of the follow up visit | |
| Secondary | Percent of adolescents engaging in protective sexual behavior Endline 2 | Percent of adolescents engaging in protective sexual behavior, defined as self-reported abstinence or consistent condom use (a condom used every time) over the past 6 months | In the 6 month time period prior to the date of the follow up visit | |
| Secondary | Percent of adolescents engaging in transactional sex in past 6 months Endline 1 | self-reported | In the 6 months prior to the date of the follow up visit | |
| Secondary | Percent of adolescents engaging in transactional sex in past 6 months Endline 2 | self-reported | In the 6 months prior to the date of the follow up visit | |
| Secondary | Percent of adolescents reporting two or more sexual partners in the past 6 months Endline 1 | self-reported | In the 6 months prior to the date of the follow up visit | |
| Secondary | Percent of adolescents reporting two or more sexual partners in the past 6 months Endline 2 | self-reported | In the 6 months prior to the date of the follow up visit | |
| Secondary | Mean HIV knowledge score Endline 1 | HIV knowledge score calculated based on the answers to survey questions | Nine months after baseline interview | |
| Secondary | Mean HIV knowledge score Endline 2 | HIV knowledge score calculated based on the answers to survey questions | Eighteen months after baseline interview | |
| Secondary | Mean financial literacy score Endline 1 | Financial literacy score calculated based on the answers to survey questions | Nine months after baseline interview | |
| Secondary | Mean financial literacy score Endline 2 | Financial literacy score calculated based on the answers to survey questions | eighteen months after baseline interview | |
| Secondary | Percent of adolescents participating in savings group Endline 1 | Percent of adolescents participating in savings group (self report) | Nine months after baseline interview | |
| Secondary | Percent of adolescents participating in savings group Endline 2 | Percent of adolescents participating in savings group (self report) | eighteen months after baseline interview | |
| Secondary | Percent of adolescents opening savings account Endline 1 | Percent of adolescents opening savings account (self report) | Nine months after baseline interview | |
| Secondary | Percent of adolescents opening savings account Endline 2 | Percent of adolescents opening savings account (self report) | eighteen months after baseline interview | |
| Secondary | Mean total amount of savings in past 1 year Endline 1 | Mean total amount of savings starting from prior to enrollment in the study up to 9 months of participation in the study | In the one year prior to the date of the 9 month follow up visit | |
| Secondary | Mean total amount of savings in past 1 year Endline 2 | Mean total amount of savings in past 1 year reported by adolescents (self report) | In the one year prior to the date of the 18 month follow up visit | |
| Secondary | Percent of adolescents saving for education Endline 1 | Percent of adolescents saving for education (self report) | Nine months after baseline interview | |
| Secondary | Percent of adolescents saving for education Endline 2 | Percent of adolescents saving for education (self report) | eighteen months after baseline interview | |
| Secondary | Percent of adolescents whose caregiver provided money for savings Endline 1 | Percent of adolescents whose caregiver provided money for savings (self report) | Nine months after baseline interview | |
| Secondary | Percent of adolescents whose caregiver provided money for savings Endline 2 | Percent of adolescents whose caregiver provided money for savings (self report) | eighteen months after baseline interview | |
| Secondary | Percent of adolescents who participate in household budgeting Endline 1 | Percent of adolescents who participate in household budgeting (self report) | Nine months after baseline interview | |
| Secondary | Percent of adolescents who participate in household budgeting Endline 2 | Percent of adolescents who participate in household budgeting (self report) | eighteen months after baseline interview |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |